From: Controlled-release hydromorphone and risk of infection in adults: a systematic review
Characteristics | Number (%) |
---|---|
Study characteristics (n = 7) |  |
Year of publication | Â |
2020 | 4 (80%) |
2021 | 1 (20%) |
Geographical region | Â |
Canada | 5 (100%) |
Study design | Â |
Cohort | 4 (80%) |
Case control | 1 (20%) |
Study duration | Â |
 ≤ 1 year | 2 (40%) |
 ≤ 5 years | 2 (40%) |
 > 5 years | 1 (20%) |
Setting | Â |
Multi-site | 4 (80%) |
Single site | 1 (20%) |
Patient characteristics | Â |
Total # patients | 4,208 |
Mean number of patients (range) | 4,015 (26–3,790) |
Mean % female patients (range) | 48.425 (42.5–54) |
Age (mean/median) | Â |
 ≤ 40 years | 1 (20%) |
 > 40 years | 1 (20%) |
Not reported | 3 (60%) |
Studies reporting on outcomesa | Â |
Infective endocarditis | 1 |
HCV | 4 |
HIV | 2 |
Comorbiditiesa | Â |
Alcohol use disorder | 3 |
Stimulant use disorder | 1 |
Psychiatric diagnosis | 3 |
HCV | 3 |
Untreated HCV | 1 |
HIV | 3 |
Hepatitis B | 2 |
Chronic liver disease | 1 |
Coronary artery disease | 1 |
Congestive heart failure | 1 |
Self-harm | 2 |
Psychiatric medication at enrolment | 1 |
HAART | 1 |
Injection related complication | 1 |
Not reported | 2 |